With the exclusion of ACE2 polymorphism, the genetic association with hypertension traits (hopefully) involving larger cohorts in future studies, the safety of continuing the consumption of ACEI/ARB among patients is, for now, certain [96]. This evidence concerns the gene ACE2 and hypertensive disorder.